All times are in Eastern Time unless otherwise noted.
- This event has passed.
Lunch & Learn – On the Path Toward #insulin4all: Access, Affordability, and Biosimilars
November 18, 2021 @ 1:00 pm–2:00 pm EST
Join Doctors for America for a Lunch & Learn in observance of National Diabetes Awareness Month and the centennial of the insulin’s discovery, focused on insulin access and affordability issues and the emergence of biosimilar insulin formulas.
During this session, we will go over the previous lack of biosimilar forms of insulin, which has been a contributing factor in the insulin pricing crisis, as well as the recent emergence of new biosimilars and what it means for the future of diabetes treatment. We will also learn about diabetes patient advocacy and what the emergence of biosimilars means to patients.
Our esteemed panelists are:
Kasia Lipska, MD, MHS is an endocrinologist at the Yale School of Medicine and a Clinical Investigator at the Yale-New Haven Hospital Center for Outcomes Research and Evaluation (CORE). Her research program seeks to better understand the balance of benefits and harms of glucose-lowering therapy in older adults with type 2 diabetes. Dr. Lipska works at CORE on the development of ambulatory care quality measures for the Centers for Medicare & Medicaid Services (CMS). She is currently leading the development of an outcome measure of care quality among people with diabetes mellitus.
Laura Marston, JD has lived with Type 1 diabetes for 25 years, since age 14. She is a video game attorney, and a relentless patient advocate for affordable insulin in the United States. Laura recently spoke alongside California Representative Katie Porter as part of a coordinated push to have the FTC investigate insulin price fixing among competitors. Laura’s current focus is on drafting and instituting federal insulin list price caps.
Ameet Sarparwari, JD, PhD is an Assistant Professor of Medicine at Harvard Medical School and the Assistant Director of the Program On Regulation, Therapeutics, And Law (PORTAL) within the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital. Dr. Sarpatwari’s current work focuses on risk evaluation and mitigation strategies, biosimilars, orphan drug policy, and drug development and pricing.